ResearcherYangzhou UniversityActive in the last 2 years
Gengyu Sha
Matched on ORCID iD 0000-0002-6117-0033; OpenAlex author ID A5023470225. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2022: 1 paper · 2023: 1 paper · 2024: 1 paper
Papers 3
- Exosomal non-coding RNA: A new frontier in diagnosing and treating pancreatic cancer: A review. Co-author DOI 10.1016/j.ijbiomac.2024.130149↗
- Intratumoral microbiota: A new force in diagnosing and treating pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.216031↗
- Galectins Are Central Mediators of Immune Escape in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14225475↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Daorong Wang · 3 shared papers, 2022–2024 · strength 0.68
- Paper Exosomal non-coding RNA: A new frontier in diagnosing and treating pancreatic cancer: A review. DOI 10.1016/j.ijbiomac.2024.130149↗
- Paper Intratumoral microbiota: A new force in diagnosing and treating pancreatic cancer. DOI 10.1016/j.canlet.2022.216031↗
- Paper Galectins Are Central Mediators of Immune Escape in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers14225475↗
- Dong Tang · 3 shared papers, 2022–2024 · strength 0.68
- Paper Exosomal non-coding RNA: A new frontier in diagnosing and treating pancreatic cancer: A review. DOI 10.1016/j.ijbiomac.2024.130149↗
- Paper Intratumoral microbiota: A new force in diagnosing and treating pancreatic cancer. DOI 10.1016/j.canlet.2022.216031↗
- Paper Galectins Are Central Mediators of Immune Escape in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers14225475↗
- Wenjie Zhang · 2 shared papers, 2023–2024 · strength 0.48
- Zhengting Jiang · 2 shared papers, 2022–2024 · strength 0.46
- Zhengting Jiang · 1 shared paper, 2023 · strength 0.22
- Zhilin Zhang · 1 shared paper, 2023 · strength 0.22
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.